- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03239769
Compare the Aesthetic Effect of Different Thyroidectomies
August 7, 2017 updated by: Xiao Ma, Peking University Cancer Hospital & Institute
A Study to Evaluate and Compare the Surgical Outcomes, Aesthetic Effects and Incision Length of Different Access Procedures in Patients With DTC
One hundred twenty female patients who underwent thyroidectomy were evenly distributed into three groups: conventional access (CA), aesthetic principles access (APA) and minimally invasive access (MIA).
The Patient and Observer Scar Assessment Scale (POSAS) was used as the assessment tool for the linear scar.
After one year follow-up, the cosmetic outcomes were assessed.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A prospective study in patients with DTC at the Department of Head and Neck Surgery at Perking University Cancer Hospital (also called Beijing Cancer hospital).
A total of 120 female patients who underwent surgical treatment for DTC were enrolled in the study from June 2012 to June 2014.
All patients were diagnosed with DTC through preoperative fine needle aspiration biopsy pathology.
These patients were individually randomly assigned (1:1:1 ratio) into the conventional access group (CA), the aesthetic principles access group (APA) or the minimally invasive access group (MIA).
Lobectomy plus ipsilateral central lymph node dissection (CLND) was adopted in each patient.
DTC staging was T1N0M0 or T1N1M0.
The investigators retrieved the patients' information, including age, incision length, incision closure procedure, incidence of complications, and cosmetic assessment from patients' medical records.
Patients with other medical diseases, such as diabetes or obesity, a smoking history, a keloid tendency, a history of radiotherapy to the head and neck, or with incomplete information, were excluded.
RLN function was evaluated by electronic fiber laryngoscopy 6 months postoperatively.
The follow-up time was 12.3 months.
The research was reviewed and approved by the Ethics Committee of Peking University Cancer Hospital, and informed consent was obtained from all patients to publish the information/image(s) in an online open-access publication.
The study was open-label with no blinding of patients, clinicians, or research staff.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients diagnosed with DTC through preoperative fine needle aspiration biopsy pathology.
- DTC staging was T1N0M0 or T1N1M0.
- Female
- Age over 18 years
- Subjects who fully understand the study process, participate voluntarily
Exclusion Criteria:
- Patients with other medical diseases, such as diabetes or obesity, a smoking history, a keloid tendency, a history of radiotherapy to the head and neck, or with incomplete information.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: conventional access group (CA)
A 4- to 5-cm incision was created, subplatysmal flaps were raised, and the strap muscles were mobilized.
Then, the superior pole of the thyroid gland was exposed and the gland was delivered through the surgical incision, and the thyroid isthmus was divided.
Finally, CLND was performed.
The strap muscles were re-approximated with No.1 silk suture.
The full-thickness skin was closed with interrupted monofilament.
|
Thyroidectomies have different approaches.
The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
|
|
Experimental: aesthetic principles access group (APA)
The key difference focused on the disposal incision using aesthetic principles, which are depicted below.
The incision was protected by Vaseline ointment.
Excessive skin traction was avoided to prevent the injury on the skin edge.
Bleeding was stanched with a low-power bipolar coagulation device.
The surgical field does not have to be pulled in every direction to show the full operation field.
The cervical linea alba was closed by continuous sutures with 3-0 absorbable Vicryl sutures.
Interrupted sutures of 4-0 Vicryl were used to re-approximate the subcutaneous tissues.
The epidermis was fixed with 3M steri-strip elastic skin closures rather than skin sutures.
|
Thyroidectomies have different approaches.
The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
|
|
Experimental: minimally invasive access group (MIA)
With the MIA approach, a shorter incision of between 3 and 4 cm was created.
The procedure used the Harmonic scalpel as an auxiliary device.
First, the isthmus was divided.
Second, the lower pole of the thyroid was dissected from the adipose tissue, and the inferior thyroid vessels were divided close to the thyroid gland for mobilization.
The RLN and parathyroid glands were carefully dissected.
Third, the superior pole of the thyroid gland was disconnected.
Finally, CLND was performed.
The closure procedure for the incision was similar to that for APA.
|
Thyroidectomies have different approaches.
The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient and Observer Scar Assessment Scale (POSAS)
Time Frame: 12 months post-operation
|
The POSAS scale is a reliable and feasible tool for linear scar evaluation.
The POSAS included the observer scale and the patient scale.
The Observer Scar Assessment Scale (OSAS) score was obtained by the same observer; this scale includes 5 items graded on a 10-point scale with 1 indicating normal skin and 10 indicating the worst scar imaginable.
A summary score of 5 indicates normal skin, and a summary score of 50 is the worst possible scar result.
The Patient Scar Assessment Scale (PSAS) consists of 6 items.
All items are graded by the patient on a 10-point scale; a summary score of 6 to 60 represents the range from normal skin to the worst imaginable scar.
After scoring the items, the observer and the patients rated the overall scar appearance on a visual analogue scale corresponding to a 10-point scale.
|
12 months post-operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Scar length
Time Frame: 12 months post-operation
|
Using ruler to measure the length of the scar, accuracy to millimeter
|
12 months post-operation
|
|
Operation time
Time Frame: Day 1 (on the day of operation)
|
From incision to suture completed (record the duration from start of operation to the end of operation)
|
Day 1 (on the day of operation)
|
|
Blood loss
Time Frame: Day 1 (on the day of operation)
|
Blood loss from incision to suture completed (record the blood loss from start of operation to the end of operation)
|
Day 1 (on the day of operation)
|
|
Amount of drainage
Time Frame: till extubation, an average of 48 hours post-operation
|
Record the amount of the drainage from end of surgical procedure to extubation of drainage
|
till extubation, an average of 48 hours post-operation
|
|
Duration of drainage
Time Frame: till extubation, an average of 48 hours post-operation
|
Record the duration (days) of the drainage, from end of surgical procedure to extubation of drainage
|
till extubation, an average of 48 hours post-operation
|
|
Number of CLND
Time Frame: up to 2 weeks post-operation
|
Record the number of central lymph nodes
|
up to 2 weeks post-operation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiao Ma, Doctor, Peking University Cancer Hospital & Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2012
Primary Completion (Actual)
June 1, 2015
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
August 1, 2017
First Submitted That Met QC Criteria
August 3, 2017
First Posted (Actual)
August 4, 2017
Study Record Updates
Last Update Posted (Actual)
August 9, 2017
Last Update Submitted That Met QC Criteria
August 7, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XMa-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Differentiated Thyroid Carcinoma (DTC)
-
Alpha Fusion Inc.RecruitingDTC - Differentiated Thyroid CancerJapan
-
Ruijin HospitalCompletedDifferentiated Thyroid Cancer (DTC) | Robotic AssistanceChina
-
Eisai Korea Inc.CompletedDifferentiated Thyroid Carcinoma (DTC)Korea, Republic of
-
Thomas Jefferson UniversityActive, not recruitingDifferentiated Thyroid Cancer (DTC) | Poorly Differentiated Thyroid CancerUnited States
-
Zhejiang UniversityNot yet recruitingNeoadjuvant Therapy | Differentiated Thyroid Carcinoma (DTC)China
-
University of Maryland, BaltimoreNot yet recruitingPapillary Thyroid Carcinoma | Papillary Thyroid Microcarcinoma | Differentiated Thyroid Cancer (DTC)United States
-
Yansong LinActive, not recruitingDTC - Differentiated Thyroid CancerChina
-
Royal Marsden NHS Foundation TrustWrightington, Wigan and Leigh NHS Foundation TrustRecruiting
-
Novartis PharmaceuticalsActive, not recruitingDifferentiated Thyroid Cancer (DTC)United States, China, Canada, Taiwan, Malaysia, Vietnam, Brazil, India, South Korea, Turkey (Türkiye), Argentina
-
Eisai Co., Ltd.CompletedDifferentiated Thyroid Cancer (DTC)China
Clinical Trials on thyroidectomy
-
Aristotle University Of ThessalonikiAHEPA University HospitalCompleted
-
Shahida Islam Medical ComplexCompleted
-
Second Military Medical UniversityUnknown
-
Kahramanmaras Sutcu Imam UniversityCompletedThyroid Diseases | Thyroid Cancer | Thyroid Nodule | Thyroid Neoplasms Benign
-
Assiut UniversityUnknown
-
Centre Hospitalier Universitaire de NīmesTerminatedGraves Disease | Goiter | Thyroid Nodule | ThyroiditisFrance
-
University of AlbertaTerminated
-
Sohag UniversityRecruitingBenign Thyroid DiseasesEgypt
-
University of Colorado, DenverCharite University, Berlin, GermanyTerminatedHypothyroidism | Postsurgical HypothyroidismUnited States
-
Tel-Aviv Sourasky Medical CenterCompletedPapillary Thyroid Cancer | Well Differentiated Thyroid Carcinoma